CX Institutional’s CRISPR Therapeutics CRSP Stock Holding History

CX Institutional’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9K	Sell	164 -10	-6%	-$540	﹤0.01%	1368
2026 Q2	$9K	Hold	174	–	–	﹤0.01%	1307
2026 Q1	$8K	Hold	174	–	–	﹤0.01%	1321
2025 Q4	$9K	Hold	174	–	–	﹤0.01%	1203
2025 Q3	$11K	Buy	174 +10	+6%	+$574	﹤0.01%	1179
2025 Q2	$8K	Hold	164	–	–	﹤0.01%	1063
2025 Q1	$6K	Buy	+164	New	+$6.95K	﹤0.01%	1049
2022 Q3	–	Sell	-10	Closed	-$1K	–	597
2022 Q2	$1K	Buy	+10	New	+$588	﹤0.01%	1126

Other funds holding CRSP

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Slow Capital Greenbrae, California $890M AUM 40.96% 1-Year Est. Return

NTV Asset Management Charleston, West Virginia $1.08B AUM 23.94% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

Canal Insurance Company Greenville, South Carolina $426M AUM 30.47% 1-Year Est. Return

Bouvel Investment Partners Phoenixville, Pennsylvania $433M AUM 51.2% 1-Year Est. Return

CX Institutional's CRSP Position: Q3 2026 in Review

CX Institutional reduced its CRISPR Therapeutics (CRSP) stake by 5.7% in Q3 2026, selling an estimated $540 and leaving 164 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1368.

CX Institutional first reported a position in CRSP in Q2 2022 and has held it in 8 quarters since. The position peaked at $11K in Q3 2025. 88 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

CX Institutional held 164 shares of CRISPR Therapeutics worth $9K as of Q3 2026.
CX Institutional sold 10 CRISPR Therapeutics shares in Q3 2026, an estimated $540.
CRISPR Therapeutics made up ﹤0.01% of CX Institutional's portfolio in Q3 2026, its #1368 holding.
CX Institutional first reported a position in CRISPR Therapeutics in Q2 2022 and has held it in 8 quarters since.
CX Institutional's CRISPR Therapeutics position peaked at $11K in Q3 2025.
88 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.